Muskelrelaxanzien bei Leber- und Nierenerkrankungen

  • H. G. Kress
Conference paper

Zusammenfassung

Leber und Nieren sind die wesentlichen Eliminationsorgane des Körpers. Erkrankungen dieser Organe beeinflussen zwangsläufig die Pharmakokinetik von Muskelrelaxanzien in Abhängigkeit vom Ausmaß der Beteiligung von Leber und/oder Nieren am globalen Exkretionsprozeß ([17]; Abb. 1). Da bei Muskelrelaxanzien eine recht enge quantitative Beziehung zwischen Plasmaspiegel und Wirkung an der motorischen Endplatte besteht, ist durch eine Änderung der Eliminationskinetik auch eine entsprechende Änderung der Wirkdauer dieser Substanzen zu erwarten [20]. Der Anästhesist muß deshalb bei der Wahl eines Muskelrelaxans, seiner kalkulierten Dosis und einer eventuellen Antagonisierung auf die veranderte Pharmakokinetik bei.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bevan DR, Archer D, Donati F, Ferguson A, Higgs BD (1982) Antagonism of pancuronium in renal failure: no recurarization. Br J Anaesth 54: 63–68PubMedCrossRefGoogle Scholar
  2. 2.
    Bencini AF, Scaf AH J, Sohn YJ, Kersten-Kleef UW, Agoston S (1986) Hepatobiliary disposition of vecuronium bromide in man. Br J Anaesth 58: 988–995PubMedCrossRefGoogle Scholar
  3. 3.
    Bencini AF, Mol WEM, Scaf AHJ, Kersten UW, Wolters KTP, Agoston S, Meijer DKF (1988) Uptake and excretion of vecuronium bromide and pancuronium bromide in the isolated perfused rat liver. Anesthesiology 69: 487–492PubMedCrossRefGoogle Scholar
  4. 4.
    Canfell PC, Castagnoli N, Fahey M, Hennis PJ, Miller RD (1986) The metabolic disposition of laudanosine in dog, rabbit, and man. Drug Metab Disp 14: 703–708Google Scholar
  5. 5.
    Cohen EN, Brewer HW, Smith D (1967) The metabolism and elimination of d- tubocurarine-3H. Anesthesiology 28: 309–317PubMedCrossRefGoogle Scholar
  6. 6.
    Cronnelly R, Stanski DR, Miller RD, Sheiner LB, Sohn YJ (1979) Renal function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology 51: 222–226PubMedCrossRefGoogle Scholar
  7. 7.
    Cronnelly R, Stanski DR, Miller RD, Sheiner LB (1980) Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther 28: 78–81PubMedCrossRefGoogle Scholar
  8. 8.
    Duvaldestin P, Henzel D (1982) Binding of tubocurarine, fazadinium, pancuronium and ORG NC45 to serum proteins in normal man and in patients with cirrhosis. Br J Anaesth 54: 513–516PubMedCrossRefGoogle Scholar
  9. 9.
    Duvaldestin P, Lebrault C, Chauvin M (1985) Pharmacokinetics of muscle relaxants in patients with liver disease. Clin Anaesth 3: 293–306Google Scholar
  10. 10.
    Duvaldestin P, Agoston S, Henzel D, Kersten UW, Desmonts JM (1978) Pancuronium pharmacokinetics in patients with liver cirrhosis. Br J Anaesth 50: 1131–1136PubMedCrossRefGoogle Scholar
  11. 11.
    Fahey MR, Morris RB, Miller RD, Nguyen TL, Upton RA (1981) Pharmacokinetics of ORG NC45 ( Norcuron) in patients with and without renal failure. Br J Anaesth 53: 1049–1053Google Scholar
  12. 12.
    Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M, Canfell C, Castagnoli K, Hennis PJ (1984) The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 61: 699–702PubMedCrossRefGoogle Scholar
  13. 13.
    Fung DL, White DA, Jones BR, Gronert GA (1991) The onset of disuse-related potassium efflux to succinylcholine. Anesthesiology 75: 650–653PubMedCrossRefGoogle Scholar
  14. 14.
    Ingram MD, Sclabassi RJ, Cook DR, Stiller RL, Benett MH (1986) Cardiovascular and electroencephalographic effects of laudanosine in “nephrectomized” cats. Br J Anaesth [Suppl] 58: 14S–18SGoogle Scholar
  15. 15.
    Khuenl-Brady KS, Sharma M, Chung K, Miller RD, Agoston S, Caldwell JE (1989) Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. Anesthesiology 71: 919–922PubMedCrossRefGoogle Scholar
  16. 16.
    Lagasse RS, Katz RI, Petersen M, Jacobson MJ, Poppers PJ (1990) Prolonged neuromuscular blockade following vecuronium infusion. J Clin Anesth 2: 269–271PubMedCrossRefGoogle Scholar
  17. 17.
    Lebowitz PW, Ramsey FM (1989) Muscle relaxants. In: Barash PG, Cullen BF, Stoelting RK (eds) Clinical anesthesia. Lippincott, PhiladelphiaGoogle Scholar
  18. 18.
    Lebrault C, Berger JL, D’Hollander AA, Gomeni R, Henzel D, Duvaldestin P (1985) Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) in patients with cirrhosis. Anesthesiology 62: 601–605PubMedCrossRefGoogle Scholar
  19. 19.
    Magorian T, Wood P, Caldwell JE, Szenohradszky J, Segredo V, Sharma H, Gruenke LD, Miller RD (1991) Pharmakokinetics, onset, and duration of action of rocuronium in humans: normal vs hepatic dysfunction. Anesthesiology 75: A1069CrossRefGoogle Scholar
  20. 20.
    Miller RD (1982) Pharmacokinetics of competitive muscle relaxants. Br J Anaesth 54: 161–167PubMedCrossRefGoogle Scholar
  21. 21.
    Miller RD (1985) Effect of renal disease. Clin Anaesth 3: 307–313Google Scholar
  22. 22.
    Miller RD, Way WL, Hamilton WK, Layzer RB (1972) Succinylcholine-induced hyperkalemia in patients with renal failure? Anesthesiology 36: 138–141PubMedCrossRefGoogle Scholar
  23. 23.
    Motsch J, Hennis PJ, Zimmermann FA, Agoston S (1989) A model for determining the influence of hepatic uptake of nondepolarizing muscle relaxants in the pig. Anesthesiology 70: 128–133PubMedCrossRefGoogle Scholar
  24. 24.
    Nigrovic V, Fox JL (1991) Atracurium decay and the formation of laudanosine in humans. Anesthesiology 74: 446–454PubMedCrossRefGoogle Scholar
  25. 25.
    Nigrovic V, Klaunig JE, Smith SL, Schultz NE (1987) Potentiation of atracurium toxicity in isolated rat hepatocytes by inhibition of its hydrolytic degradation pathway. Anesth Analg 66: 512–516PubMedGoogle Scholar
  26. 26.
    Østergaard D, Jensen E, Jensen FS, Viby Mogensen J (1991) The duration of action of mivacurium-induced neuromuscular block in patients homozygous for the atypical plasma cholinesterase gene. Anesthesiology 75: A774CrossRefGoogle Scholar
  27. 27.
    O’Kelly B, Jayais P, Veroli P, Lhuissier C, Ecoffey C (1991) Dose requirements of vecuronium, pancuronium, and atracurium during orthotopic liver transplantation. Anesth Analg 73: 794–798PubMedCrossRefGoogle Scholar
  28. 28.
    Pittet JF, Tassonyi E, Schopfer C, Morel DR, Mentha G, Fathi M, Le Coultre C, Steinig DA, Benakis A (1990) Plasma concentrations of laudanosine, but not of atracurium, are increased during the anhepatic phase of orthotopic liver transplantation in pigs. Anesthesiology 72: 145–152PubMedCrossRefGoogle Scholar
  29. 29.
    Powell DR, Miller RD (1975) The effect of repeated doses of succinylcholine on serum potassium in patients with renal failure. Anesth Analg 54: 746–748PubMedCrossRefGoogle Scholar
  30. 30.
    Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastila WB, El-Sayad HA (1988) The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). Anesthesiology 68: 723–732PubMedCrossRefGoogle Scholar
  31. 31.
    Segredo V, Mathay MA, Sharma ML, Gruenke LD, Caldwell JE, Miller RD (1990) Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. Anesthesiology 72: 566–570PubMedCrossRefGoogle Scholar
  32. 32.
    Segredo V, Shin YS, Sharma ML, Gruenke LD, Caldwell JE, Khuenl-Brady KS, Agoston S, Miller RD (1991) Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (ORG 7268) in cats. Anesthesiology 74: 1052–1059PubMedCrossRefGoogle Scholar
  33. 33.
    Slater RM, Pollard BJ, Doran BRH (1988) Prolonged neuromuscular blockade with vecuronium in renal failure [Letter]. Anaesthesia 43: 250–251PubMedCrossRefGoogle Scholar
  34. 34.
    Somogyi AA, Shanks CA, Triggs EJ (1977) Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. Br J Anaesth 49: 1103–1108PubMedCrossRefGoogle Scholar
  35. 35.
    Vine P, Boheimer N, Ward S, Weatherley B, Buick A, Smith I (1986) Laudanosine pharmacokinetics after bolus atracurium in patients with hepato-biliary dysfunction. Br J Anaesth [Suppl] 58: 1327 PGoogle Scholar
  36. 36.
    Ward S, Neill EAM (1983) Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth 55: 1169–1172PubMedCrossRefGoogle Scholar
  37. 37.
    Ward S, Weatherley BC (1986) Pharmacokinetics of atracurium and its metabolites. Br J Anaesth [Suppl] 58: 6S–10SGoogle Scholar
  38. 38.
    Westra P, Keulemans GTP, Houwertjes MC, Hardonk MJ, Meijer DKF (1981) Mechanisms underlying the prolonged duration of action of muscle relaxants caused by extra- hepatic cholestasis. Br J Anaesth 53: 217–227PubMedCrossRefGoogle Scholar
  39. 39.
    Yate PM, Flynn PJ, Arnold RW, Weatherley BC, Simmonds RJ, Dopson T (1987) Clinical experience and plasma laudanosine concentrations during the infusion of atracurium in the intensive therapy unit. Br J Anaesth 59: 211–217PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg New York 1992

Authors and Affiliations

  • H. G. Kress

There are no affiliations available

Personalised recommendations